Price
Financials
Consolidated, Rs crore| Dec 2012 | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 271 | 276 | 227 | 297 | 325 | 363 | 314 | 320 | 325 | 358 | 334 | 339 |
| Expenses | 251 | 253 | 232 | 266 | 290 | 323 | 297 | 301 | 292 | 317 | 303 | 302 |
| Operating Profit | 20 | 23 | -5 | 30 | 35 | 40 | 17 | 19 | 33 | 41 | 31 | 37 |
| OPM % | 7% | 8% | -2.2% | 10% | 11% | 11% | 5% | 6% | 10% | 11% | 9% | 11% |
| Other Income | 8 | 7 | 9 | 7 | 3 | 3 | 2 | 4 | 2 | 12 | 1 | 4 |
| Interest | 10 | 5 | 8 | 9 | 11 | 14 | 12 | 12 | 16 | 13 | 12 | 12 |
| Depreciation | 12 | 16 | 13 | 15 | 15 | 16 | 12 | 10 | 12 | 13 | 14 | 15 |
| Profit before tax | 6 | 9 | -17 | 13 | 13 | 13 | -5 | 1 | 7 | 27 | 5 | 15 |
| Tax % | -28% | -50% | -61% | 0% | -1% | 23% | 0% | 2% | 0% | 23% | 24% | 11% |
| Net Profit | 8 | 13 | -7 | 13 | 13 | 10 | -5 | 0 | 6 | 22 | 4 | 13 |
| EPS in Rs | 1.49 | 2.34 | -1.16 | 2.36 | 2.30 | 1.84 | -0.80 | 0.04 | 1.02 | 3.69 | 0.57 | 1.95 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 348 | 763 | 809 | 749 | 784 | 834 | 1,066 | 1,084 | 1,207 | 1,314 | 1,356 |
| Expenses | 292 | 689 | 797 | 863 | 771 | 763 | 943 | 967 | 1,098 | 1,195 | 1,214 |
| Operating Profit | 55 | 73 | 12 | -113 | 13 | 71 | 123 | 117 | 109 | 119 | 141 |
| OPM % | 16% | 10% | 1.5% | -15% | 1.7% | 9% | 12% | 11% | 9% | 9% | 10% |
| Other Income | 17 | 19 | 59 | 32 | 57 | 22 | 41 | 18 | 23 | 21 | 19 |
| Interest | 5 | 10 | 15 | 22 | 30 | 32 | 44 | 32 | 50 | 63 | 52 |
| Depreciation | 23 | 26 | 31 | 38 | 38 | 38 | 41 | 53 | 59 | 47 | 54 |
| Profit before tax | 43 | 57 | 24 | -141 | 2 | 24 | 80 | 50 | 23 | 30 | 54 |
| Tax % | 15% | 8% | -1% | -3% | -88% | -13% | -26% | -5% | -32% | 21% | |
| Net Profit | 37 | 53 | 25 | -137 | 4 | 27 | 101 | 53 | 30 | 24 | 45 |
| EPS in Rs | 10.94 | 5.10 | -28.38 | 0.78 | 5.49 | 18.25 | 9.37 | 5.34 | 3.95 | 7.23 | |
| Dividend Payout % | 22% | 16% | 20% | 0% | 128% | 5% | 13% | 16% | 19% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 11% | 7% | 3% | ||
| Compounded Profit Growth | % | 30% | -35% | 107% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | 8% | 18% | 12% | 6% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 12 |
| Reserves | 168 | 212 | 230 | 97 | 108 | 74 | 211 | 261 | 291 | 367 |
| Borrowings | 79 | 192 | 257 | 339 | 327 | 329 | 353 | 506 | 692 | 739 |
| Other Liabilities | 94 | 219 | 167 | 219 | 219 | 235 | 285 | 266 | 332 | 364 |
| Total Liabilities | 351 | 632 | 663 | 664 | 663 | 648 | 860 | 1,044 | 1,327 | 1,482 |
| Fixed Assets | 175 | 214 | 255 | 269 | 244 | 248 | 278 | 365 | 383 | 529 |
| CWIP | 2 | 21 | 55 | 35 | 30 | 12 | 52 | 81 | 114 | 76 |
| Investments | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 16 |
| Other Assets | 169 | 397 | 352 | 360 | 389 | 387 | 529 | 598 | 823 | 861 |
| Total Assets | 351 | 632 | 663 | 664 | 663 | 648 | 860 | 1,044 | 1,327 | 1,482 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 31 | -6 | 58 | -34 | 37 | 59 | 51 | 35 | 40 | 84 |
| Cash from Investing Activity | -32 | -78 | -106 | -21 | 10 | -32 | -77 | -161 | -164 | -145 |
| Cash from Financing Activity | -9 | 91 | 43 | 54 | -40 | -28 | 32 | 117 | 131 | 51 |
| Net Cash Flow | -9 | 8 | -5 | -0 | 7 | -1 | 5 | -9 | 7 | -9 |
| Free Cash Flow | 5 | -90 | -48 | -60 | 46 | 24 | -30 | -126 | -152 | -63 |
| CFO/OP | 71% | -3% | 513% | 29% | 294% | 84% | 50% | 30% | 42% | 79% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 90 | 81 | 91 | 90 | 69 | 79 | 89 | 106 | 97 |
| Inventory Days | 115 | 182 | 103 | 97 | 89 | 108 | 90 | 113 | 122 | 128 |
| Days Payable | 83 | 200 | 105 | 158 | 152 | 137 | 141 | 140 | 159 | 152 |
| Cash Conversion Cycle | 112 | 72 | 79 | 30 | 27 | 40 | 28 | 62 | 69 | 72 |
| Working Capital Days | 94 | 90 | 89 | 72 | 77 | 64 | 63 | 89 | 103 | 118 |
| ROCE % | 20% | 9% | -27% | 3% | 13% | 19% | 12% | 8% | 8% |
Fundamentals
Market Cap₹ Cr.
Current Price₹ 429
Book Value₹ 67.2
ROCE7.94 %
ROE5.91 %
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)3%
Compounded Profit Growth (TTM)107%
Consolidated figures.
Valuation
Market capRs 2,577 Cr
Enterprise valueRs 3,313 Cr
P/E (TTM)57.02x
Price to book6.80x
Price to sales1.90x
EV / EBITDA20.64x
EV / EBIT31.23x
EV / sales2.44x
Price to cash flow30.61x
Earnings yield1.75%
P/E, 3-year average38.17x
P/B, 3-year average2.87x
P/E, 5-year average25.72x
P/B, 5-year average2.74x
Profitability
Operating margin (excl. other income)9.03%
Operating margin (incl. other income)10.65%
EBITDA margin11.84%
Pre-tax margin3.95%
Net profit margin3.33%
Net margin, latest quarter3.86%
ROE6.97%
ROCE8.80%
ROA1.69%
ROE, 3-year average12.98%
ROCE, 3-year average9.73%
ROA, 3-year average3.27%
ROE, 5-year average26.20%
ROCE, 5-year average13.44%
ROA, 5-year average5.44%
ROIC (approx.)7.52%
Tax rate20.98%
Other income / net worth5.63%
Growth
Sales growth (latest year)8.83%
Profit growth (latest year)-21.35%
Sales CAGR, 3 years7.21%
Sales CAGR, 5 years10.88%
Profit CAGR, 3 years-38.18%
Profit CAGR, 5 years44.51%
Sales growth QoQ1.72%
Profit growth QoQ244.47%
Sales growth YoY (latest quarter)6.04%
Profit growth YoY (latest quarter)5136.00%
Per share
EPS (TTM)Rs 7.52
EPS (latest year)Rs 3.95
EPS (latest quarter)Rs 2.18
EPS, 3-year averageRs 6.22
EPS, 5-year averageRs 8.48
Book value per shareRs 62.99
Sales per shareRs 225.50
Cash flow per shareRs 14.00
Free cash flow per shareRs -10.48
Dividend per share, 3-year averageRs 1.25
Dividend per share, 5-year averageRs 1.30
Dividends
Dividend payout, 3-year average17.38%
Dividend payout, 5-year average13.35%
Efficiency
Asset turnover0.89x
Fixed asset turnover2.48x
Inventory turnover3.55x
Inventory days103 days
Debtor days97 days
Debtors turnover3.78x
Creditor days152 days
Cash conversion cycle72 days
Working capital days118 days
Leverage
Total debtRs 739 Cr
Cash and bankRs 3 Cr
Net debtRs 736 Cr
Debt to equity1.95x
Net debt / EBITDA4.59x
Interest coverage2.02x
Owners' fund to total sources25.56%
Debt to assets49.90%
Cash flow
Cash from Operating Activity (latest year)Rs 84 Cr
Cash from Investing Activity (latest year)Rs -145 Cr
Cash from Financing Activity (latest year)Rs 51 Cr
Net Cash Flow (latest year)Rs -9 Cr
Free cash flow (latest year)Rs -63 Cr
FCFE (approx.: FCF + change in debt)Rs -16 Cr
Cash from ops / profit, 5 years1.14x
Sales to cash flow15.61x
Statement figures
Net sales (TTM)Rs 1,356 Cr
Net sales (latest year)Rs 1,314 Cr
Sales (latest quarter)Rs 339 Cr
Operating profit excl. other income (latest year)Rs 119 Cr
Operating profit (latest quarter)Rs 37 Cr
Other income (TTM)Rs 19 Cr
EBITDA (TTM)Rs 161 Cr
PBDT (TTM)Rs 108 Cr
Profit before tax (TTM)Rs 54 Cr
Tax (latest year)Rs 6 Cr
Net profit (TTM)Rs 45 Cr
Net profit (latest year)Rs 24 Cr
Net profit (latest quarter)Rs 13 Cr
Depreciation (TTM)Rs 54 Cr
Depreciation (latest quarter)Rs 15 Cr
Interest (TTM)Rs 52 Cr
Cost of goods sold (latest year)Rs 844 Cr
Total expenditure (latest year)Rs 1,195 Cr
Total income (latest year)Rs 1,335 Cr
Share capitalRs 12 Cr
ReservesRs 367 Cr
Shareholders' fundsRs 379 Cr
Total assetsRs 1,482 Cr
Net blockRs 529 Cr
Capital work in progressRs 76 Cr
InvestmentsRs 16 Cr
ReceivablesRs 348 Cr
InventoryRs 238 Cr
Other liabilitiesRs 364 Cr
Shares outstanding (crore)6.01
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | SHASUNPHAR | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +10.1% | -2.8% | +12.9 pts |
| 1 month | +9.7% | -6.8% | +16.5 pts |
| 3 months | +10.9% | -7.6% | +18.5 pts |
| 6 months | +28.3% | +0.4% | +27.9 pts |
| 1 year | +103.3% | -9.9% | +113.2 pts |
| 2 years | +470.3% | -13.6% | +483.8 pts |
| 3 years | +175.2% | +14.2% | +161.1 pts |
| 5 years | +499.4% | +27.9% | +471.5 pts |
Red flags
F-score 4 of 8| explain | Low interest cover Interest cover 1.5x in 2015 |
| look | Profit leans on other income Other income was 71% of pre-tax profit in 2015 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Sep 2015Sales ₹339 Cr +5.9% vs Sep 2014.
Net profit ₹13 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2015-08-04 | Annual General Meeting/ Interim Dividend - Re 1/- Per Share (Purpose Revised) | |
| 2014-07-30 | Annual General Meeting / Dividend - Re 1/- Per Share | |
| 2013-07-23 | Annual General Meeting / Dividend - Rs 1.50/- Per Share | |
| 2012-07-23 | Annual General Meeting / Dividend Rs 0.40 Per Share | |
| 2012-03-21 | Interim Dividend Rs.2/- Per Share (Purpose Revised) | |
| 2011-07-20 | Annual General Meeting And Dividend Re.0.30 Per Share | |
| 2010-07-23 | Annual General Meeting And Dividend Re.1/- Per Share | |
| 2009-09-14 | Annual General Meeting | |
| 2008-07-17 | Agm/Div-Re.1 Per Share | |
| 2007-07-13 | Agm/Div-Re.0.90 Per Sh | |
| 2007-02-05 | Int Div-Re.0.80 Per Sh | |
| 2006-07-12 | Agm/Div-Rs.1.70/- Per Sh |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Shasun Pharmaceuticals Ltd(Merged)?
Shasun Pharmaceuticals Ltd(Merged) (SHASUNPHAR) has a market capitalisation of Rs Cr. at the 2015-11-17 close.
What were Shasun Pharmaceuticals Ltd(Merged)'s latest quarterly results?
In the Sep 2015 quarter, Shasun Pharmaceuticals Ltd(Merged) sales was Rs 339 Cr (+5.9% vs Sep 2014) and net profit was Rs 13 Cr.